Orphazyme initiates directed issue and private placement of shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Board of Directors has resolved to initiate a directed issue and private placement of up to an aggregate of 7,032,937 new shares and existing shares, at market price as determined by the Board of Directors of the Company through a book-building process, corresponding to approximately 35.16% of the Company’s currently registered share capital.
Orphazyme initiates directed issue and private place
Read morePreliminary results for 2019 and financial outlook for 2020
Feb 4, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today releases preliminary results for 2019 as well as the financial outlook for 2020.
Preliminary results for 2019 and financial outlook
Read moreCapital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Jan 31, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business Ltd. (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
Capital increase of 20650 shares in Orphazyme
Read moreResolutions passed at the Extraordinary General Meeting in Orphazyme A/S
Jan 25, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the shareholders passed the following resolutions.
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jan 7, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreOrphazyme announces US Early Access Program for Niemann-Pick disease Type C
Jan 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme announces early access program
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S - CORRECTION
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Notice to convene EGM correction
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Read moreOrphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces 12-month interim data from an open-label extension of a phase 2/3 study of arimoclomol, an investigational product candidate in development for Niemann-Pick disease Type C (NPC).
Orphazyme reports positive arimoclomol data
Read moreMajor shareholder announcement
Dec 19, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of December 18, 2019 holds a total 991,557 shares in the Company, corresponding to 4.96% of the share capital and that Danske Bank as of December 18, 2019 controls 7.42% of the voting rights in the Company.
Major shareholder announcement
Read more